|
|
|
|
Abstract Title |
|
Details
(Venue: Messe München GmbH, Munich)
|
|
RE-DUAL PCITM |
|
High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCITM |
|
SPAF-A346 (1160.186)
15:50 – 16:40, 26 Aug 2018, Moderated Poster station- Poster Area
|
|
The effect of age on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCITM |
|
SPAF-A360 (1160.186)
15:50 – 16:40, 26 Aug 2018, Moderated Poster station- Poster Area
|
|
The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCITMtrial |
|
SPAF-A356 (1160.186)
10:05 - 10:55, 27 Aug 2018, Moderated Poster station- Poster Area
|
|
Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCITM subgroup analysis) |
|
SPAF-A358 (1160.186)
8:30 - 12:30, 28 Aug 2018, Best Posters screen - Poster Area
|
|
GLORIATM-AF
|
|
Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIATM-AF registry |
|
SPAF-A343 (1160.129/136/171)
14:00 – 18:00, 26 Aug 2018, Posters- Poster Area
|
|
Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: Data from GLORIATM-AF |
|
SPAF-A354 (1160.129/136/171)
14:00 – 18:00, 26 Aug 2018, Posters- Poster Area
|
|
When are Atrial Fibrillation Patients at Risk to Discontinue Anticoagulation Treatment? Results from the GLORIATM-AF Registry |
|
SPAF-A349 (1160.129/136/171)
14:00 – 18:00, 27 Aug 2018, Posters- Poster Area
|
|
A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIATM-AF Phase III baseline characteristics; (1160.129/136/171) |
|
SPAF-A347 (1160.129/136/171)
08:30 – 12:30, 27 Aug 2018, Posters- Poster Area
|
|
Geographic region, stroke risk and renal function strongly affect treatment choice for stroke prevention in patients with non-valvular AF: results from the GLORIATM-AF registry program |
|
SPAF-A353 (1160.129/136/171)
10:05 – 10:55, 28 Aug 2018, Moderated Poster station- Poster Area
|
|
Others |
|
Evaluation of VTE-BLEED for predicting intracranial or fatal bleedings in stable anticoagulated patients with venous thromboembolism |
|
VTE-A72 (Study TBC)
12:35, 25 Aug 2018, Moderated Poster station- Poster Area
|
|
Safety and Effectiveness of Dabigatran Relative to Warfarin in Routine Care – Final results from a long-term monitoring program; (1160.207) |
|
SPAF-A357 (1160.207)
12:35 - 13:25, 25 Aug 2018, Moderated Poster station - Poster Area
|
|
Trauma victims requiring dabigatran reversal with idarucizumab in RE-VERSE AD |
|
SPAF-A356 (1160.186)
08:30 - 12:30, 27 Aug 2018, Posters- Poster Area
|
|
Making sense of real-world evidence: addressing the uncertainties surrounding anticoagulation for stroke prevention in non-valvular atrial fibrillation |
|
MAPOR-A42
TBC
|
|